150 related articles for article (PubMed ID: 31258461)
1. Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein.
Shimozawa A; Fujita Y; Kondo H; Takimoto Y; Terada M; Sanagi M; Hisanaga SI; Hasegawa M
Front Neurosci; 2019; 13():595. PubMed ID: 31258461
[TBL] [Abstract][Full Text] [Related]
2. Propagation of pathological α-synuclein in marmoset brain.
Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
[TBL] [Abstract][Full Text] [Related]
3. Levodopa Rescues Retinal Function in the Transgenic A53T Alpha-Synuclein Model of Parkinson's Disease.
Tran KKN; Wong VHY; Vessey KA; Finkelstein DI; Bui BV; Nguyen CTO
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255235
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Kumar V; Singh D; Singh BK; Singh S; Mittra N; Jha RR; Patel DK; Singh C
Mol Cell Biochem; 2018 Jul; 444(1-2):149-160. PubMed ID: 29198021
[TBL] [Abstract][Full Text] [Related]
5. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.
Bernis ME; Babila JT; Breid S; Wüsten KA; Wüllner U; Tamgüney G
Acta Neuropathol Commun; 2015 Nov; 3():75. PubMed ID: 26612754
[TBL] [Abstract][Full Text] [Related]
6. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
7. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Szego ÉM; Gerhardt E; Kermer P; Schulz JB
Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
[TBL] [Abstract][Full Text] [Related]
8. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
9. L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
Schmitt I; Kaut O; Khazneh H; deBoni L; Ahmad A; Berg D; Klein C; Fröhlich H; Wüllner U
Mov Disord; 2015 Nov; 30(13):1794-801. PubMed ID: 26173746
[TBL] [Abstract][Full Text] [Related]
10. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.
Tehranian R; Montoya SE; Van Laar AD; Hastings TG; Perez RG
J Neurochem; 2006 Nov; 99(4):1188-96. PubMed ID: 16981894
[TBL] [Abstract][Full Text] [Related]
12. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
[TBL] [Abstract][Full Text] [Related]
13. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
15. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
16. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
17. [Prion-like Propagation of Pathological α-Synuclein in Vivo].
Masuda-Suzukake M; Hasegawa M
Yakugaku Zasshi; 2019; 139(7):1007-1013. PubMed ID: 31257247
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
19. Analysis of α-Synuclein Pathology in PINK1 Knockout Rat Brains.
Creed RB; Goldberg MS
Front Neurosci; 2018; 12():1034. PubMed ID: 30686993
[TBL] [Abstract][Full Text] [Related]
20. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]